A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
about
Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancerRecognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignanciesRasburicase in the management of tumor lysis: an evidence-based review of its place in therapyTumor lysis syndrome: new challenges and recent advances.Controlling serum uric acid using febuxostat in cancer patients at risk of tumor lysis syndromeReduced administration of rasburicase for tumor lysis syndrome: A single-institution experienceThe optimal single-dose regimen of rasburicase for management of tumour lysis syndrome in children and adults: a systematic review and meta-analysis.Prevention and treatment of tumor lysis syndrome, and the efficacy and role of rasburicase.PharmGKB summary: uric acid-lowering drugs pathway, pharmacodynamics.Kidney diseases associated with haematological cancers.Tumor lysis syndrome: review of pathogenesis, risk factors and management of a medical emergency.Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer.Single dose rasburicase in the management of tumor lysis syndrome in childhood acute lymphoblastic leukemia: A case series.PharmGKB summary: methylene blue pathway.Rasburicase-induced methemoglobinemia in two African-American female patients: an under-recognized and continued problem.Mortality following rasburicase-induced methemoglobinemia.Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis.Fixed-Dose Rasburicase in Overweight and Obese Patients Versus Normal-Weight Patients.Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents.Single dose Rasburicase is a clinically effective pharmacoeconomic approach for preventing tumour lysis syndrome in children with high tumour burden.Guidelines for treatment of renal injury during cancer chemotherapy 2016.Low-dose rasburicase in hematologic malignancies.FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk.Efficacy of Single Dose Rasburicase (1.5 mg) for Prophylaxis and Management of Laboratory Tumor Lysis Syndrome
P2860
Q24194387-4579A211-CDA7-435C-B32C-96406F45D985Q26862904-E3644D13-2AB8-4946-B739-B9EF43458104Q28082089-6E3819A0-43AB-457F-8E07-653B428B1C54Q33595615-631D8494-34D6-4595-8A59-2ECA20689345Q34141630-56EC76D5-16F7-4114-B24F-B706B966E20CQ35742173-7D9BC8B1-251E-42B8-B10C-749FA3D314E6Q36204470-C889E488-13C6-40BA-9931-3275AD8EE693Q37629599-E16CF62B-27F7-41A0-84FE-33D070345011Q38219092-E780D910-651B-4068-9501-262DEA89E4ACQ38513113-CDBC16CF-03D5-4254-99D4-77A7611B889DQ38656591-CC37C68E-D326-43AC-84D5-42A2874B41BCQ38921102-D91068EC-1BAF-40FB-B296-2D47E1257296Q41119377-487729DB-3819-411A-88BA-AFC31E5EBD72Q41890556-A204C180-A13B-43C9-9768-ACEB7FEEB807Q44793048-975862C9-A1E5-42AC-9724-66540381219AQ45062960-7BECBBAB-2AAE-401B-BB19-02CFA954508AQ46599361-B929868B-2BE0-4400-B7D6-CB16432B5572Q47580177-4DAE51CD-7BCC-4011-944E-2544B83BAFFAQ47887134-D36307A5-C5DF-4097-9B05-AFCC45465940Q48179378-B8B3055D-AE7A-4DA8-9945-40435276200CQ50063006-2338AE68-30EE-4449-AE15-EC3E25B08C8CQ51105458-9ADFE225-92A3-4F3A-BAD4-B918D8DAE396Q53405416-58F4E236-012C-44BC-B9E0-6DCE41451BA5Q58125072-4F5CD914-0D96-4490-BF0A-BA5A2DF0395D
P2860
A randomized trial of a single-dose rasburicase versus five-daily doses in patients at risk for tumor lysis syndrome.
description
2011 nî lūn-bûn
@nan
2011 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A randomized trial of a single ...... risk for tumor lysis syndrome.
@ast
A randomized trial of a single ...... risk for tumor lysis syndrome.
@en
type
label
A randomized trial of a single ...... risk for tumor lysis syndrome.
@ast
A randomized trial of a single ...... risk for tumor lysis syndrome.
@en
prefLabel
A randomized trial of a single ...... risk for tumor lysis syndrome.
@ast
A randomized trial of a single ...... risk for tumor lysis syndrome.
@en
P2093
P2860
P356
P1433
P1476
A randomized trial of a single ...... risk for tumor lysis syndrome.
@en
P2093
A Rodriguez
C E Bueso-Ramos
F B Hagemeister
F Samaniego
J E Cortes
J E Romaguera
P2860
P304
P356
10.1093/ANNONC/MDR490
P577
2011-10-19T00:00:00Z